New Zealand health regulators haveapproved the sale and marketing of Sativex

From Norml in NZ

December 2, 2010 - Wellington, New Zealand

Wellington, New Zealand: New Zealand health regulators haveapproved the sale and marketing of Sativex, an oral spray consisting of natural cannabis extracts (primarily the plant cannabinoids THC and cannabidiol aka CBD) as a treatment for symptoms of multiple sclerosis.

The spray is produced in the United Kingdom and will be exported to New Zealand, where it will be available by prescription.

Sativex has already been approved as a prescription drug in Canadaand the United Kingdom and is pending regulatory approval in Spain, France, Germany, and Italy.